Remtolumab (ABT-122) 是一种双变量域免疫球蛋白，可以中和肿瘤坏死因子α (TNFα) 和IL-17A。Remtolumab 显示出对 TNFα 和 IL-17A 的双重抑制。Remtolumab 可用于类风湿关节炎 (RA) 研究。
| 生物活性 | Remtolumab (ABT-122) is a dual-variable domain immunoglobulin that neutralises both tumor necrosis factor α (TNFα) andIL-17A. Remtolumab shows dual inhibition of TNFα andIL-17A. Remtolumab can be used for rheumatoid arthritis (RA) research[1][2]. |
| IC50& Target | |
| CAS 号 | |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
m.cnreagent.com